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Background: HOIP is the catalytic subunit of the linear ubiquitination chain assembly
complex (LUBAC) that is essential for NF-κB signaling and thus proper innate
and adaptive immunity. To date only one patient with HOIP deficiency has been
reported with clinical characteristics that include autoinflammation, immunodeficiency,
amylopectinosis, and systemic lymphangiectasia.
Case: We sought to identify a genetic cause of a disease for an 8 year-old girl who
presented with early-onset immune deficiency and autoinflammation.
Methods: Targeted next generation sequencing of 352 immune-related genes was
performed. Functional studies included transcriptome analysis, cytokine profiling, and
protein analysis in patients’ primary cells.
Results: We identified biallelic variants in close proximity to splice sites (c.1197G>C
and c.1737+3A>G) in the RNF31 gene. RNA extracted from patient cells showed
alternatively spliced transcripts not present in control cells. Protein expression of HOIP
and LUBAC was reduced in primary cells as shown by western blotting. Patient-derived
fibroblasts demonstrated attenuated IL-6 production, while PBMCs showed higher TNF
production after stimulation with proinflammatory cytokines. RNA sequencing of whole
blood RNA and PBMCs demonstrated a marked transcriptome wide change including
differential expression of type I interferon regulated genes.
Conclusion: We report the second case of HOIP deficiency with novel compound
heterozygous mutations in RNF31 and distinct clinical and molecular features. Our results
expand on the clinical spectrum of HOIP deficiency and molecular signatures associated
with LUBAC deficiency.
Keywords: LUBAC, HOIP, HOIL1, SHARPIN, primary immunodeficiency, autoinflammation, CVID
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Sanger Sequencing

INTRODUCTION

Coding regions as well as flanking intronic regions of the RNF31
gene (RefSeq: NM_017999.4) were amplified by AmpliTaq Gold
Fast PCR Master Mix (Thermo Fisher Scientific) and sequenced
on 3130xl Genetic Analyzer (Applied Biosystems). For the
subcloning analysis, the genomic region spanning from intron
6 to intron 9 of RNF31 was PCR amplified, subcloned using
TOPO TA cloning kit (Invitrogen) and sequenced. The data were
analyzed by Sequencher (Gene Codes).

The signaling activity of nuclear factor kappa B (NF-κB)
pathway is tightly regulated by post-transcriptional modifications
including ubiquitination. Linear and Lys (K) 63 ubiquitination
generally promote signaling activity, whereas K48 Ub chains
act as a cellular protein degradation signal. The linearubiquitin assembly complex (LUBAC), consisting of HOIL1-interacting protein (HOIP), Heme-oxidized IRP2 ubiquitin
ligase-1 (HOIL-1) and SHANK-associated RH domain interactor
(SHARPIN), specifically conjugates linear (Met1) ubiquitin
chains to various target proteins in the canonical NF-κB pathway
(1). LUBAC activity is counter-regulated by the linear ubiquitin
specific deubiquitinase OTULIN. Defects in linear and K63
ubiquitination and deubiquitination processes result in immune
dysregulations in mice and humans (2).
Patients with defects in the LUBAC components develop
immunodeficiency, autoinflammation, and amylopectinosis of
cardiac and/or skeletal muscle (Table S1) (3, 4). The previously
reported HOIP deficiency is also noted to have lymphangiectasia
leading to the malabsorption in the gastrointestinal tract,
hypoalbuminemia, and systemic edema. Molecular investigations
demonstrated that patients’ fibroblasts and B cells were
unresponsive to immune stimuli and failed to upregulate NF-κB
activity consistent with the patient’s observed immunodeficient
phenotype. In contrast to immune responses in fibroblasts,
peripheral blood mononuclear cells (PBMCs) of HOIP and
HOIL1-deficient patients were highly responsive to IL-1
stimulation and produced proinflammatory cytokines IL-6
and MIP-1α.
Here we describe a second case of HOIP deficiency
with compound heterozygous mutations in RNF31,
who was clinically diagnosed with common variable
immunodeficiency (CVID). Similar to the first case with
HOIP deficiency, the patient presented with systemic
inflammatory features but without evidence of amylopectinosis
or lymphangiectasia. We also expand our understanding
of the clinical manifestation of LUBAC deficiency using
transcriptome analysis.

RT-PCR
Whole blood RNA was extracted using PAXgene Blood RNA
Kit (Qiagen) and reverse transcribed by SuperScript III FirstStrand Synthesis SuperMix (Invitrogen). cDNA sequences of
RNF31 from exons 6 to 10 was PCR amplified, subcloned and
Sanger sequenced.

Intracellular Cytokine Staining
PBMCs were cultured with IL-1β (R/D, 10 ng/ml) and Monensin
for 3, 6, and 24 h, were immunelabeled with antibodies against
CD14 (BD; 557154), TNF (BD; 554513), IL-6 (BD; 561441),
and IL-1β (Abcam; 16168) and with Yellow Live/Dead (Thermo;
L34967), and were analyzed by CytoFLEX (BD).

Lymphocyte Activation Assay
PBMCs were incubated with CellTrace violet (1 µM, Cell
Proliferation Kit, Thermo), stimulated with anti-IgM (10 µg/ml,
Jackson Lab; 109-006-129), CD40L (100 ng/ml, Enzo; ALX522110-C010), IL-4 (10 ng/ml, Peprotech; 200-04), IL-21 (100 ng/ml,
Peprotech; 200-21), CpG (1µM, Enzo; ALX746-006-C100),
BAFF (100 ng/ml, Enzo ALX-522-025-C010), anti-CD3 (1 µg/ml,
eBioscience; 16-0037-85), anti-CD28 (1 µg/ml, eBioscience; 160289-85) and PHA (1 µg/ml, Sigma; L9017). Seventy-two hours
later the cells were stained with surface markers and analyzed
by flow cytometer. Staining was performed with following
antibodies from BD: CD3 (UCHT1), CD4 (RPAT4), CD8
(RPAT8), CD19 (HIB19) and CD80 (L307.4). For p-STAT1
detection, staining was performed using following antibodies
from BD: CD4 (RPAT4), CD8 (SK1) and p-STAT1 (4a), and from
Biolegend: CD3 (UCHT1), CD14 (M5E2) and CD45RA (HI100).

METHODS

Immunoblotting

Targeted Next Generation Sequencing

Whole-cell lysates were prepared using ice-cold M-PER
(Thermo Fisher Scientific) supplemented with protease inhibitor
(Roche) and phosphatase inhibitor (Roche). Proteins were
separated with Novex Tris-Glycine Gel Systems (Invitrogen)
and transferred to PVDF membranes with iBlot2 systems
(Invitrogen). After incubation with antibodies indicated below,
proteins were visualized using ECL Plus Western blotting
substrate (Thermo Fisher). Following antibodies were used for
immunoblotting: HOIP (Abcam; ab46322), HOIL-1 (Sigma;
MABC576), SHARPIN (CST; 12541), β –Actin (Santa Cruz;
sc-47778), IkBα (CST; 4814), p-IkBα (CST; 2859), p-IKKα/β
(CST; 2697), IKKα (CST; 11930), and TRIM25 (BD; 610570).
Control primary fibroblast from an adult donor was purchased
from ATCC (CS-201-012).

Capture-based targeted next generation sequencing of 352 genes
related to primary immunodeficiency and autoinflammation
was conducted as described previously (5). Briefly, capture
of the target regions, including the coding exons plus 50
flanking bases of 352 genes was performed with reagents from
a custom designed HaloPlex Target Enrichment kit (Agilent
Technologies), according to the HaloPlex Target Enrichment
System Protocol. Samples were sequenced on the Ion Proton
sequencer using the Ion PI chip v3 (Life Technologies). Read
mapping and variant calling were performed using the Ion
Torrent Suite software v4.4.2, against the UCSC hg19 reference
genome. Variants were annotated using ANNOVAR (http://
annovar.openbioinformatics.org/) (6).
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LUBAC Reconstitution and
Immunoprecipitation

mother (11). On examination at the age of 7 years old
she was noted to have eczematous dermatitis (Figure 1A),
splenomegaly, and clubbing of her toes and fingers. Skin biopsy
demonstrated superficial perivascular chronic inflammation
with dense infiltration of CD4+ and focal MPO+ cells
(Figure 1B and Figure S1). Upper gastrointestinal endoscopy
did not reveal histological evidence of lymphangiectasia. Serum
creatine kinase, aldolase and echocardiography were normal,
and muscle biopsy was not performed due to lack of clinical
symptoms. Immunophenotyping of leukocyte surface markers
demonstrated low memory B cells (Table S2). Consistent
with the previous report of HOIP deficiency, the patient’s
B cell proliferation and CD80 expression were impaired
after CD40 ligand (CD40L) stimulation and preserved after
B cell receptor stimulation (Figures S2A,B). T lymphocyte
proliferation following various stimuli were normal (Figure S3).
Currently, the patient is stable with minimal inflammation on
subcutaneous immunoglobulin supplementation.

RNF31 ORF was subcloned into MSCV-N-Flag-HA-IRES-PURO
vector (Addgene; 41033) using Gateway system (Invitrogen).
The two mutant RNF31 plasmids lacking exon 7 (c.8101197) and exon 9 (c.1489-1737) were constructed by sitedirected mutagenesis. SHARPIN (#50014) and HOIL-1 (#50016)
expressing plasmids were purchased from Addgene. These
plasmids were transiently expressed in HEK293T cells using
Lipofectamine 2000 (Invitrogen). After 48 h cells were lysed
using lysis buffer containing 30 mM Tris-HCl, 150 mM NaCl, 1%
Triton-X 100, 1% protease inhibitor mixture and phosphatase
inhibitor (Roche). For immunoprecipitations, 500 µg of lysates
were incubated with anti HA affinity gel (Sigma; E6779)
overnight at 4◦ C, washed five times with lysis buffer and
subjected to immunoblotting.

RNA Sequencing
Total RNA was isolated from whole blood collected in PAXgene
Blood RNA Tubes using PAXgene Blood RNA Kit (PreAnalytiX)
per manufacturer’s instructions, and PBMCs using TRIzol
(Thermo Fisher Scientific). Total RNA with high quality (RIN
> 8) was used for cDNA library preparation using the TruSeq
Stranded mRNA Library Preparation kit for NeoPrep (Illumina).
Sequencing was performed on an Illumina HiSeq 3000 System
in a 1 × 50 bp single read mode. Sequenced reads were mapped
against the human reference genome (GRCh37) using TopHat
v2.1.1 (7). Reads mapped to hemoglobin genes were removed
from further analysis. Mapped reads were quantified using
HTSeq (8). All the count data were normalized using TCC (9) and
differentially expressed genes were detected using edgeR (10).
Pathway enrichment analysis was performed using Ingenuity
Pathway Analysis (IPA) software (Qiagen), respectively. The
original RNAseq data is uploaded and available online (Gene
Expression Omnibus: GSE118901).

RESULTS
By targeted next generation sequencing of 352 immune-related
genes we identified two single nucleotide variants in RNF31,
which encodes HOIP: c.1197G>C; p.Q399H and c.1737+3A>G
(Figure 1C and Table 1). The mother was heterozygous for the
latter variant while her paternal sample was not available. We
demonstrated that these variants are inherited in trans by subcloning of the patient’s genomic DNA (Figure S4). We showed
that the patient’s RNA is aberrantly spliced and lacking exon
7 (c.810-1197) or exon 9 (c.1489-1737) (Figures 1D,E), while
her mother’s RNA was alternatively spliced and lacking only
exon 9. The protein expression of HOIP, as well as HOIL-1 and
SHARPIN, were markedly diminished in the patient’s PBMCs,
suggesting the destabilization of the LUBAC (Figure 2A). The
exon 7 skipped transcript is out-of-frame and is translated into
39 kDa truncated protein, while the exon 9 skipped transcript
is in-frame and lacks 84 amino acids (p.Arg496 to p.Lys579).
To test the stability of these mutant proteins, we overexpressed
individual RNF31 mutant transcripts in HEK293T cells and coexpressed them together to mimic compound heterozygosity.
The protein levels of these mutants were not noticeably reduced
after overexpression, suggesting that instability of truncations in
patient cells is likely bypassed by overexpression (Figure 2B).
HOIP binds to SHARPIN and HOIL-1 via its UbiquitinAssociated (UBA) domain (p.Arg480-p.Arg623), and these
interactions are indispensable for the stabilization of LUBAC.
Therefore, we next tested by immunoprecipitation whether
these interactions are affected. As expected, the exon 7 deleted
HOIP lacking the entire UBA domain had no interaction with
SHARPIN and HOIL-1 (Figure 2C). Interestingly, although the
interaction of exon 9 deleted HOIP with HOIL-1 was unchanged,
its interaction with SHARPIN was markedly diminished. Recent
structural analyses of LUBAC suggested that SHARPIN and
HOIL-1 bind to two different modules within the UBA domain
of HOIP (UBA-1: p.Arg480-p.Gln542 and UBA-2: p.Leu565p.Arg623, respectively) (12, 13). The exon 9 mutant protein

Statistics
All the statistical analyses were performed using R version 3.3.3
(R Foundation for Statistical Computing).

Patient
We studied an 8-year-old girl of mixed American ancestry
born to non-consanguineous parents. At 7 months old she
was diagnosed with polyarticular juvenile idiopathic arthritis
after developing hip swelling and knee contracture. She
was treated with corticosteroids, methotrexate, and eventually
improved on TNF blockade with etanercept. At age 3,
she developed recurrent fevers and suffered from severe
bacterial, viral and fungal infections even after discontinuation
of immunosuppressants (Table S1). Although she did not
demonstrate hypogammaglobulinemia (IgG 645, IgM 25, and
IgA 965 mg/dl), she lacked response to pneumococcal antigens
upon vaccination. Given her clinical history, she was diagnosed
with common variable immune deficiency (CVID). She also
had a history of borderline cognitive delay and absence
seizures, which might be attributed to a duplication on
the chromosome 15q13.3 inherited from her asymptomatic
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FIGURE 1 | Clinical characteristics of the HOIP deficient patient. (A) Eczematous dermatitis. (B) Histopathology of the skin biopsy sample. (C) Information about the
pedigree and the detected variants. (D) Genomic architecture of the RNF31 gene through exons 6 to 10. ZF: zinc finger; NZF: Npl4-zinc finger; UBA:
ubiquitin-associated. (E) Subcloning of the RT-PCR product demonstrated multiple forms of aberrant splicing. The table demonstrates the number of clones.

(lacking p.Arg496 to p.Lys579) lacks a large portion of the
UBA-1 domain of HOIP that is required for the interaction
with SHARPIN, and the loss of this interaction could cause
destabilization of the endogenous LUBAC complex. Thus, our
in vitro results indicate that both mutations affect the stability
of LUBAC.
We next tested the signaling activity of NF-κB by
stimulating patient’s PBMCs using TNF. Consistent with
the immunodeficient phenotype and prior reports, these cells
displayed reduced phosphorylation and decreased degradation
of I-kappa-B alpha (IκBα), and delayed phosphorylation of
IκB kinase α/β (IKKα/β) suggesting impaired activation of
NF-κB (Figure 3A). Stimulated patient’s CD14+ monocytes
displayed increased accumulation of intracellular TNF, but
not IL-1β or IL-6, in contrast to lower responsiveness of the
patient’s fibroblasts (Figure 3B and Figure S5). Serum cytokine
measurement showed significantly increased levels of IL-6 at
multiple time points, which is consistent with previous reports
(Figure S6).
We then studied the genome-wide impact of HOIP deficiency
by RNA sequencing of the patient’s unstimulated whole blood
sample and isolated PBMCs collected during asymptomatic
periods. Transcriptome-wide clustering demonstrated a unique
profile for the proband compared to unrelated age-matched
healthy controls (Figures 4A,B and Figure S7A). Pathway
analysis demonstrated enrichment of interferon (IFN) α2regulated genes exemplified by MX1, TREX1, IFIH1, IRF7, IRF9,
and STAT1 (Figures 4C–E, Figure S7B, and Table S3). The type

Frontiers in Immunology | www.frontiersin.org

TABLE 1 | RNF31 mutations identified in the patient.
Chromosome

Genomic
alterationa

cDNA
alterationb

Exon/
ExAC
Amino
intron
allele
acid
frequency
alteration

14

g.24619657G>C c.1197G>C

14

g.24620591A>G c.1737+3A>G -

p.Q399H

Exon 7

0

Intron 9

0

a Genome
b cDNA

reference: GRCh37.
reference: NM_017999.4.

I IFN signature, as defined by the set of 28 genes upregulated in
monogenic interferonopathies (14), was enriched in the patient’s
PBMCs (Figure 4F), and less remarkable in the whole blood
(Figure S7C). Additional pathway analysis of the RNAseq data
identified a prominent TNF gene expression signature in the
patient’s PBMCs exemplified by CCL2, CCL4, CXCL1, and CD163
(Figures 4E,G). Overall, the interferon-response gene cluster
was ranked higher than the cluster of TNF-induced genes in
PBMCs (Table S3). Type I IFN and TNF-mediated inflammatory
transcriptome signatures were also identified in the PBMCs
of the asymptomatic mother (Figures 4D,F,G and Figure S7A),
which suggests a subclinical impact of HOIP haploinsufficiency
in mononuclear hematopoietic cells.
The molecular pathophysiology of autoinflammation in
LUBAC deficient patients is still unclear, in particular with
regard to the interferon pathway. Inn et al previously reported
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FIGURE 2 | Effects of the identified RNF31 mutations on LUBAC assembly. (A) The expression of LUBAC subunits in PBMCs. HOIP (long) indicates long exposure. C,
unrelated age-matched control; Pt, the HOIP deficient patient; Mo, the mother. (B) Overexpression of HA-tagged mutant HOIP plasmids with SHARPIN and HOIL-1 in
HEK293T cells. To mimic compound heterozygosity, two mutant plasmids were co-transfected. e7_del and e9_del indicate skipping of exon 7 and exon 9,
respectively. (C) Immunoprecipitation of HA-tagged HOIP to assess the LUBAC assembly, in the presence of SHARPIN and HOIL-1 overexpression.

that the LUBAC plays a role in regulating antiviral responses
via degradation of TRIM25, a positive regulator of type I
IFN production (15). Specifically, the baseline expression

Frontiers in Immunology | www.frontiersin.org

of TRIM25 protein is shown to be upregulated in HOIL1 knock-out and HOIP knock-down mouse embryonic
fibroblasts (MEFs) (15). However, we did not observe increased
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FIGURE 3 | Molecular consequences of the HOIP deficiency. (A) PBMCs from the HOIP deficient patient showed decreased levels of phosphorylated IκBα and
delayed phosphorylation of IKKα/β after TNF stimulation (20 ng/ml) compared with an unrelated healthy control. (B) Cytokine responsiveness of CD14+ monocyte
subsets in the HOIP deficient patient and unrelated healthy controls (N = 2). Representative FACS plots are shown. Analysis was performed in triplicates. Two-way
factorial ANOVA with Bonferroni adjustment was performed for the statistical analysis. *adjusted p < 0.05.

monocytes, suggesting a lineage-specific role of LUBAC in
T cells.

expression of TRIM25 in unstimulated HOIP deficient
patient’s PBMCs, compared to control cells (Figure S8). To
investigate potential lineage-specific type I IFN signaling
we stimulated patient’s PBMCs with IFNα and examined T
cell subsets and monocytes. We observed that the patient’s
T cells, especially CD4+ /CD45RA+ and CD8+ /CD45RA+
naïve subsets, had higher levels of phosphorylated STAT1
compared to healthy control cells (Figure 5). Interestingly,
this induction was not observed in the patient’s CD14+

Frontiers in Immunology | www.frontiersin.org

DISCUSSION
We herein describe the second case of HOIP deficiency
manifesting with CVID, autoinflammation but without evidence
for lymphangiectasia or amylopectinosis. The two cases of
HOIP deficiency shared similar clinical features of immune
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FIGURE 4 | Inflammatory signatures of the HOIP deficient patient. (A,B) Heatmaps showing genome-wide expression change in the patient’s whole blood (A) and
PBMCs (B) obtained during symptom-free periods. C1-3, M, and P indicate healthy unrelated controls, the mother and the patient, respectively. (C,D) Heatmaps
(Continued)
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FIGURE 4 | showing the expression patterns of differentially expressed genes regulated by IFNα2 in whole blood (C) and PBMCs (D). (E) M-A plot analysis showing
differentially expressed genes between PBMCs of the HOIP deficient patient and unrelated controls. Red dots indicate genes differentially expressed with statistical
significance (edgeR, p < 0.001). (F) Heatmap showing the expression of 28 genes in PBMCs that are known to be upregulated in monogenic type I
interferonopathies. (G) Heatmap showing the expression pattern of differentially expressed genes regulated by TNF.

FIGURE 5 | Flow cytometry analysis of STAT1 phosphorylation. PBMCs were stimulated with IFNα2 (20 ng/ml) for 20 min and CD4+ , CD8+ , and CD14+ cells were
assessed for STAT1 phosphorylation.

dysregulations. They both suffered from severe bacterial and
viral infections due to low number of memory B cells and
impaired antibody production. The first HOIP deficient patient
was noted to have severe T cell defects, such as T cell lymphopenia
especially affecting naïve T population and impaired response
to T cell stimulations, consistent with previous reports of HOIP
knockdown experiments in the Jurkat cells (16) and specific
Rnf31 knock-in mice lacking the C-terminal half of the HOIP
protein (17). However, these features were not observed in
our patient, who showed normal T cell counts and normal
response to T cell receptor-mediated stimulations, which might
be attributed to her different genotype, her age, or other
environmental factors. The first reported homozygous missense
mutation p.Leu72Pro in the PUB domain of HOIP was also
shown to impair the HOIP expression and stability of the
LUBAC complex.
LUBAC plays a crucial role in regulation of innate and
adaptive immune responses. LUBAC has been shown to
maintain the stability of many receptor signaling complexes
(RSCs) including TNFR1, TLRs, IL-1R, CD40, RIG-I like
receptors and inflammasomes. These receptors are upstream of

Frontiers in Immunology | www.frontiersin.org

NF-kB pathway, which governs immune responses, cell cycle
progression and cell death. LUBAC depletion leads to attenuation
of NF-kB and the mitogen-activated protein kinases (MAPK)
mediated signaling and increases cell death. Previous reports of
patients with LUBAC deficiency demonstrated impaired NF-κB
activation in mutant fibroblasts, while IL-1β stimulated patients’
CD14+ monocytes had higher intracellular production of IL6 and IL-1β. These lineage- specific signaling findings had
been proposed to explain a complex immune phenotype of
immunodeficiency and autoinflammation in LUBAC deficient
patients (3, 4). Our data support these prior results, although
we observed increased expression of TNF in IL-1β stimulated
monocytes. High levels of IL-6 were found in the patient’s serum
samples while a significant upregulation of the type I IFNinduced transcripts was detected in PBMCs-derived RNA of the
patient. These findings suggest that hypomorphic mutations in
LUBAC could lead to hypersensitivity of myeloid cells resulting
in increased production of many proinflammatory cytokines.
Furthermore, we detected enhanced p-STAT1 signaling in
T cells but not in monocytes. Thus, the type I interferon
signature in PBMCs might be predominantly driven by T cells.

8

March 2019 | Volume 10 | Article 479

Oda et al.

Second Case of HOIP Deficiency

DATA AVAILABILITY

Consistent with this finding, our patient has a history of severe
eczematous skin rashes and her skin biopsy demonstrated a
prominent dermal and perivascular infiltration of CD4+ T
cells. Type I interferonopathy is a clinical entity in which
enhanced type I IFN signaling activity plays a central role
in its pathophysiology (18). At this point there is no strong
evidence to categorize the HOIP deficiency as a new type
I interferonopathy, and it is unclear whether these patients
would benefit from treatment with JAK inhibitors. Our patient
is not currently treated with any cytokine inhibitors and she
remains stable solely on immunoglobulin replacement therapy.
Studies of LUBAC deficient mice have suggested that mutant
cells are susceptible to cell death (apoptosis and/or necroptosis)
and this cellular defect has been shown to contribute to
an inflammatory phenotype (19–23). The dysregulation in
cell death pathway has been reported in human Mendelian
diseases characterized by attenuated NF-κB signaling, such
as RIPK1 deficiency and RELA haploinsufficiency (24–26).
Therefore, the autoinflammatory phenotype in patients with
HOIP and HOIL-1 deficiencies could be also attributed to the
aberrant activation of programmed cell death. Although the
source of autoinflammation in HOIP and HOIL1 deficiencies
are still not well-understood, dysregulated LUBAC activity is
expected to have cell-specific effects on many cellular pathways
and functions.
We did not observe amylopectinosis in our patient, although
this was not directly assessed using histopathology due to a
lack of myopathic manifestations. In addition to the previous
four cases of LUBAC deficiencies with immune dysregulation,
two recent reports further described 14 cases of HOIL1
deficient cases associated with myopathy/cardiomyopathy but
without immune phenotypes (27, 28), indicating that LUBAC
deficient patients have a spectrum of clinical manifestations.
The pathophysiology of amylopectinosis in the LUBAC
deficiency is still unclear. Of note, loss-of-function mutations
in the EPM2B gene that encodes an E3-ubiquitin ligase are
reported to cause progressive epilepsy due to polyglucosan
deposition in neuronal tissues (29), which may indicate a
common role of the ubiquitin ligases in the regulation of
glycogen metabolism. The clinical and histological absence
of lymphangiectasia in our patient is noteworthy, because
the vessel formation abnormality has been observed in the
previous HOIP-deficient patient as well as in Rnf31-knock
out mice (19). Possible explanations for this phenotypic
difference include low level residual expression of HOIP in our
patient (Figure 1E and Figure 2A), earlier age at evaluation,
or other confounding genetic causes in the first report due to
consanguinity (3).
Our study of a second HOIP-deficient patient helps both to
confirm original clinical findings and mouse models and expands
our knowledge about the clinical manifestations and mechanism
of LUBAC dependent disease. We have specifically identified
different inflammatory signatures in PBMCs that also bears
evidence for a subclinical phenotype in mutation carriers. Finally,
our case report emphasizes the spectrum of clinical features
of HOIP deficiency in children and expands the differential
diagnosis for CVID and systemic inflammation.

Frontiers in Immunology | www.frontiersin.org

The datasets generated for this study can be found in Gene
expression omnibus, GSE118901.
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The Supplementary Material for this article can be found
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2019.00479/full#supplementary-material
Figure S1 | Histological examination of the HOIP deficient patient demonstrated
dermatitis, associated with global perivascular infiltration of CD3+ and CD4+ T
cells and focal MPO+ neutrophils.
Figure S2 | B lymphocytes (CD3− CD19+ ) from the HOIP deficient patient
showed decreased response to CD40 ligand stimulation. (A) PBMCs were stained
with CellTrace Violet, cultured with various stimuli for 72 h and analyzed by flow
cytometer. (B) PBMCs were cultured with various stimuli for 72 h, and the
expression levels of CD80 were analyzed by flow cytometer. MFI: mean
fluorescence intensity. Red: the HOIP deficient patient, blue: unrelated
age-matched healthy control.
Figure S3 | Normal T lymphocyte proliferation in the HOIP deficient patient.
PBMCs were stained with CellTrace Violet, cultured with anti-CD3,
anti-CD3/CD28, or phytohemagglutinin (PHA) for 72 h, and analyzed by flow
cytometer. Gray: unstimulated, red: the HOIP deficient patient, blue: unrelated
healthy control.
Figure S4 | Subcloning of the patient’s genomic DNA demonstrated that the
RNF31 variants are inherited in trans.
Figure S5 | Cytokine responsiveness of dermal fibroblasts from the HOIP deficient
patient. Analysis was performed in triplicates. Representative FACS data are
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significance (edgeR, p < 0.001). (C) Heatmap showing the expression of
28 genes in whole blood RNA that are known to be upregulated in
monogenic type I interferonopathies.

shown below. Two-way factorial ANOVA with Bonferroni adjustment was
performed for the statistical analysis. ∗ adjusted p < 0.05.
Figure S6 | Serum IL-6 analysis of the patient and unrelated healthy controls (N =
8). The patient’s samples were taken when the patient was asymptomatic and not
placed on immunosuppressants. The ELISA measurement was performed in
technical duplicates. Mann-Whitney U test was performed for the statistical
analysis. ∗∗∗ p < 0.001.

Figure S8 | Expression levels of TRIM25 in unstimulated PBMCs of the HOIP
deficient patient. HeLa cell extract was used as a positive control for the western
blot. C, unrelated healthy control; P, HOIP deficient patient.
Table S1 | Phenotypic comparison of the LUBAC deficiency patients with immune
dysregulations.

Figure S7 | Transcriptomic features of the HOIP deficient patient. (A)
Hierarchical clustering of the RNAseq of whole blood and PBMCs of the
HOIP deficient patient. (B) M-A plot analysis showing differentially expressed
genes in whole blood RNAseq of the HOIP deficient patient and the
healthy controls. Red dots indicate gene expression levels with statistical

Table S2 | Lymphocyte surface markers.
Table S3 | Upstream pathway terms enriched in the HOIP deficient patient’s
PBMCs.
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